Therefore, we aimed to develop an intranasal nanoparticle-mediated gene therapy strategy for the treatment of PD to deliver siRNA targeting human SNCA to the brain and thereby intervene in the progression of aSyn pathology in the Thy1-aSyn mouse model. Here, THY1 is linked to Parkinson disease.